期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 131, 期 6, 页码 1322-1330出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/jid.2011.9
关键词
-
类别
资金
- Dana Foundation
- National Institutes of Health (NIH) [T32-HL07423, 1 K23AR052404]
- Doris Duke Foundation
- National Center for Research Resources (NCRR), NIH [UL1 RR024143]
- Milstein Medical Research Program
Tumor-associated macrophages (TAMs) may have an important role in tumor immunity. We studied the activation state of TAMs in cutaneous SCC, the second most common human cancer. CD163 was identified as a more abundant, sensitive, and accurate marker of TAMs when compared with CD68. CD163(+) TAMs produced protumoral factors, matrix metalloproteinases 9 and 11 (MMP9 and MMP11), at the gene and protein levels. Gene set enrichment analysis (GSEA) was used to evaluate M1 and M2 macrophage gene sets in the SCC genes and to identify candidate genes in order to phenotypically characterize TAMs. There was coexpression of CD163 and alternatively activated M2'' markers, CD209 and CCL18 (chemokine (C-C motif) ligand 18). There was enrichment for classically activated M1'' genes in SCC, which was confirmed in situ by colocalization of CD163 and phosphorylated STAT1 (signal transducer and activator of transcription 1), IL-23p19, IL-12/IL-23p40, and CD127. Also, a subset of TAMs in SCC was bi-activated as CD163(+) cells expressed markers for both M1 and M2, shown by triple-label immunofluorescence. These data support heterogeneous activation states of TAMs in SCC, and suggest that a dynamic model of macrophage activation would be more useful to characterize TAMs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据